A cross‐platform comparison including 38 samples from patients with EGFR‐mutated lung cancer from the phase 1 AURA trial analyzed the concordance between the results obtained with BEAMing, ddPCR, Therascreen, and cobas®EGFR Mutation Test using tissue results as a nonreference standard [22]. This evidence concerns the gene EGFR and lung carcinoma.